<DOC>
	<DOCNO>NCT00044616</DOCNO>
	<brief_summary>This 62-week study compare safety effectiveness fluoxetine ( ProzacÂ® ) , lithium , combination two medication , placebo treat prevent recurrent depressive episode people bipolar type II disorder .</brief_summary>
	<brief_title>Relapse Prevention Bipolar Type-II Disorder</brief_title>
	<detailed_description>Bipolar II ( BP II ) disorder characterize high recurrence major depressive episode ( MDE ) , associate substantial illness death . Unfortunately , relatively little attention give treatment BP II . Concern patient may switch depressed manic state treatment MDE impede development effective treatment BP II MDE . BP II MDE patient treat initially fluoxetine 10 week . Patients recover MDE randomize receive relapse-prevention treatment fluoxetine , lithium , combination fluoxetine lithium , placebo 1 year . Patients undergo clinical laboratory evaluation , include physical examination , bloodwork , thyroid function test , electrocardiogram ( ECG ) , urinalysis , HAM-D , YMR , CGI-S , CGI-I , adverse event scale . For information relate study , please follow link : http : //clinicaltrials.gov/show/NCT00602537</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Bipolar II Depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>